Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma
This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.
Gastric/Gastroesophageal Junction Adenocarcinoma
DRUG: Tislelizumab + SOX
Pathologic complete response rate (pCR), 3 week
The R0 resection rate after radical operation, 1 year|Major Pathological response (MPR) after radical operation, From baseline to after radical operation|Event Free Survival Rate from baseline to 1 year, from baseline to 1 year|Overall Survival rate from baseline to 1 year, From baseline to 1 year|Disease-related treatment failure rate from baseline to 1 year, From baseline to 1 year|Objective response rate from baseline to 1 year, From baseline to 1 year|Disease control rate from baseline to 1year, From baseline to 1year|Correlation between PD-L1 expression, TMB level and T cell subsets in tumour tissue samples and efficacy., 6 week|The safety from baseline to 1year, From baseline to 1year
This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.